Foreword

I am pleased to provide a preface for this comprehensive book on dyslipidemia edited by my mentee Professor Samy I. McFarlane. This book contains chapters that approach the science of lipid metabolism and the treatment of dyslipidemia from an international standpoint and in a wide variety of population groups. Several chapters deal with the etiology and treatment of dyslipidemia in high-risk populations such as those with HIV and patients with chronic kidney disease. Material in these chapters includes treatment goals in special populations and approaches to attain these goals. These special populations include Asian Indians, African Americans, and Hispanics, who are generally at a higher risk for dyslipidemia. Other chapters discuss the pathogenesis and treatment of dyslipidemia in these high-risk populations. This book also includes chapters that comprehensively discuss non-pharmacological, hygienic, and unconventional approaches to treating dyslipidemia in various populations. Included also are comprehensive discussions of the unique metabolism and responses to statin therapy in various groups, and the potential genetic factors underpinning these different responses to HMG-CoA Reductase inhibitors. This book presents unique approaches to the problem of dyslipidemia and this makes this book different from prior publications on this topic.

**II**

**Section 3**

*by Abdullah Glil Alkushi*

Novel Therapies for Dyslipidemia

*by Joseph M. Keenan*

*by Olta Tafaj Reddy*

*by Deborah R. Gustafson*

**Section 4**

Special Topics in the Management of Dyslipidemia **97**

**Chapter 6 99**

**Chapter 7 115**

**Chapter 8 129**

Adiposity and Non-Tradional Lipid Biomarkers, a Look into the Future **143**

**Chapter 9 145**

Alternative Natural Management of Dyslipidemia

Adipose Tissue Complexities in Dyslipidemias

The Role of Niacin in the Management of Dyslipidemia

**James R. Sowers, MD, FAHA** Director of Diabetes and Cardiovascular Research Center University of Missouri

Preface

Dyslipidemia is a major risk factor for cardiovascular disease that is potentially modifiable and includes a heterogenous group of disorders commonly encountered in clinical practice. While several volumes addressing dyslipidemia had been previously published, this book presents a unique overview and sheds light on several topics that have not been sufficiently addressed in the literature. In this book, we assembled a group of nationally and internationally recognized scholars in their fields to share their experience and knowledge with the readers. We also provided an introductory chapter that deciphers the highly complex lipid metabolic pathways. The book highlights the pathogenesis of atherosclerosis with a focus on the role of dyslipidemia in cardiovascular disease, thus providing a rationale to treatment targets and practice guidelines. Also, unique to this book is the discussion of lipid disorders from an international perspective, addressing high-risk populations including ethnic groups such as Indians, Asians, Hispanics, and African Americans as well as those with certain disorders that heighten their cardiovascular risk such as HIV patients, chronic kidney disease, and end stage renal disease populations. Special focus on dyslipidemia in women and the elderly is also addressed. This non-traditional volume addresses non-traditional approaches to dyslipidemia including plant products such as gum residue and red yeast rice among many food supplements commonly used around the world in highly populated nations including India and China. Furthermore, a fresh look at some of the largely abandoned pharmacologic agents such as niacin and its utility in dyslipidemia management is presented by a world expert, providing new perspective on the subject. This, in addition to discussion on postprandial dyslipidemia, is a risk factor that is often overlooked in the evaluation and management of cardiovascular disease.

Finally, an updated review on the role of PCSK9 as a modern therapeutic agent is provided, together with a chapter on the emerging role of brown adipose tissue in dyslipidemia and cardiovascular risk. This is presented by a world expert on fat metabolism who also provides future insights into this highly active area of investigation. We believe that this book, *Dyslipidemia*, provides a basic understanding as well as advanced knowledge into lipid metabolism. This book should be useful to the student, researcher, as well as busy practitioner as it highlights cutting edge

**Samy I. McFarlane MD, MPH, MBA**

State University of New York, Downstate Medical Center,

United States

information and novel therapeutic approaches to dyslipidemia.
